NEW YORK and SAN DIEGO , Dec. 31 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) announced that they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for milnacipran, a unique dual-reuptake inhibitor being developed for the treatment of fibromyalgia syndrome (FMS).

NEW YORK and SAN DIEGO , Dec. 31 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX ) and Cypress Bioscience, Inc. (Nasdaq: CYPB ) announced that they have recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for milnacipran, a unique dual-reuptake inhibitor being developed for the treatment of fibromyalgia syndrome (FMS).

Hays and northwest Kansas escaped the harshest of crimes this year.

Scientists and faith-based counselors debate whether people should forgive the unforgivable -- for the sake of their health. CLOSE your eyes and think of someone who has hurt you. The offense may be profound or small but deeply painful, a single arrow to your heart or a thousand wounding slights. The perpetrator may be a stranger -- the guy who caused your accident, the gang-banger who took ...

While dopeheads are content to rob mere convenience stores, drug dealers hit licks at your friendly neighborhood pharmacy. Money for nothin', narcotics for free. While dopeheads are content to rob mere convenience stores, drug dealers hit licks at your friendly neighborhood pharmacy. What does it take to steal tens of thousands of dollars in powerful narcotics and get away clean? Astoundingly ...

OAB: Don’t “just live with it.” Talk to your doctor to get at the cause of your overactive bladder -- and take back control.

Monday's stocks in the news

Cephalon, Inc. today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration requesting approval of TREANDA® for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma who have progressed during or following treatment with rituximab or a rituximab-containing regimen.

"I'm their last hope," licensed acupuncturist Barbara Knoll said of the patients who come through her doors. But instead of that being a defeating statement, it's an empowering one to Knoll, who runs three acupuncture clinics in Ocean County.

BOSTON (Thomson Financial) - Forest Laboratories Inc. and Cypress Biosciences Inc. said Monday they have submitted a new drug application to the Food and Drug Administration for milnacipran, a drug treatment for fibromyalgia syndrome.